Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 10010520 Combined application of isothiocyanate compound and anti-cancer medicine
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Patent
0
Date Filed
August 13, 2014
0
Date of Patent
July 3, 2018
0
Patent Application Number
14912239
0
Patent Citations Received
US Patent 11517552 Method for treating psoriasis
US Patent 10434082 Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US Patent 10722527 Abiraterone acetate lipid formulations
0
US Patent 10765656 Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US Patent 11633376 Method for treating metastatic prostate cancer
0
US Patent 11633375 Method for treating infectious diseases with isothiocyanate functional compounds
0
US Patent 11654129 Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
0
US Patent 11648230 Method for treating rheumatoid arthritis
0
US Patent 11517553 Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
Patent Inventor Names
Zhiwei Cheng
0
Chunxia Zhang
0
Jingcai Cheng
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
10010520
0
Patent Primary Examiner
Shengjun Wang
0
Find more entities like US Patent 10010520 Combined application of isothiocyanate compound and anti-cancer medicine
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
SUBSCRIBE